https://www.selleckchem.com/pr....oducts/thiomyristoyl
Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not effective in all patients and the biological basis for treatment failure remains unknown. We have analysed induced immune responses to define the mechanism of action of TNF blockers in SpA and to identify immunological correlates of responsiveness to TNFi. Immune responses to microbial and pathway-specific stimuli were analysed in peripheral blood
Like
Comment
Share
